Back to top

Analyst Blog

Leading provider of heart support technologies, ABIOMED, Inc. (ABMD - Analyst Report) announced its acquisition of an exclusive license from collaboration partner Opsens, to utilize the latter’s breakthrough optical sensor technology in the field of cardio-circulatory assist devices. In a few trading sessions following the announcement, shares of ABIOMED climbed approximately 4.0% to close at $24.95 yesterday.

Per the licensing agreement, Opsens' miniature optical pressure sensors will be integrated into ABIOMED’s flagship Impella heart pump catheters to provide robust blood pressure measurements that can help enhance Impella’s performance and ease-of-use.

Opsens' optical sensors will allow for further improvements in set-up time, besides providing high-quality pressure monitoring capability that can eventually be used to help automate the control and operation of the Impella pump in the catheterization lab.

This licensing agreement – which secures ABIOMED's rights to the technology and gives the company the right to manufacture the sensors – is the continuation of an initial partnership entered between Opsens and ABIOMED in Jan 2010.

Last month, ABIOMED had announced successful completion of patient enrolment in the Recover Right clinical trial of its Impella RP in the U.S. The company plans to use the results from the trial to apply for a Humanitarian Device Exemption (HDE) approval, for which it has already received a Humanitarian Use Device (HUD) approval in Jul 2012.

More recently, ABIOMED secured CE Mark approval to market its Impella RP (Right Peripheral) heart pump in the European Union, following which, it anticipates the U.S. Food and Drug Administration (FDA) go-ahead for this novel product by Feb 2015.

ABIOMED is witnessing strong demand for its Impella line of products as an increasing number of patients are being treated with these devices. With the last reported quarter posting double-digit rise in Impella revenues, Impella utilization continues to grow at an impressive pace.

ABIOMED presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. (ELOS - Snapshot Report), Delcath Systems, Inc. and Accuray Incorporated (ARAY - Analyst Report). While Syneron Medical and Delcath Systems both sport a Zacks Rank #1 (Strong Buy), Accuray retains a Zacks Rank #2 (Buy).

Read the Full Research Report on ARAY
Read the Full Research Report on ABMD
Read the Full Research Report on ELOS
Read the Full Research Report on DCTH

Zacks Investment Research

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%